Particularly, MEC‐1 cells are Epstein–Barr virus‐positive CLL cells with a TP53 mutation, complex karyotype and overexpression of Bcl‐2, and are thus able to mimic the characteristics of CLL patients who are at high risk of developing resistance to ibrutinib [15]. Here, BCL2 is linked to B-cell chronic lymphocytic leukemia.